

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Raltegravir Pediatric Formulation

Version 3.1      Revision Date: 26.09.2023      SDS Number: 20369-00025      Date of last issue: 20.03.2023  
Date of first issue: 09.10.2014

---

### SECTION 1: Identification of the substance/mixture and of the company/undertaking

#### 1.1 Product identifier

Trade name : Raltegravir Pediatric Formulation

#### 1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-stance/Mixture : Pharmaceutical

Recommended restrictions on use : Not applicable

#### 1.3 Details of the supplier of the safety data sheet

Company : MSD  
Innishannon  
County Cork - Ireland

Telephone : 353 214329300

E-mail address of person responsible for the SDS : EHSDATASTEWARD@msd.com

#### 1.4 Emergency telephone number

1-908-423-6000

---

### SECTION 2: Hazards identification


#### 2.1 Classification of the substance or mixture

##### Classification (REGULATION (EC) No 1272/2008)

|  |  |
|--|--|
| Serious eye damage, Category 1                               | H318: Causes serious eye damage.               |
| Reproductive toxicity, Category 2                            | H361d: Suspected of damaging the unborn child. |
| Specific target organ toxicity - single exposure, Category 3 | H335: May cause respiratory irritation.        |

#### 2.2 Label elements

##### Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms : 

Signal word : Danger

Hazard statements : H318 Causes serious eye damage.

---

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Raltegravir Pediatric Formulation

Version 3.1      Revision Date: 26.09.2023      SDS Number: 20369-00025      Date of last issue: 20.03.2023  
Date of first issue: 09.10.2014

H335 May cause respiratory irritation.  
H361d Suspected of damaging the unborn child.

Precautionary statements : **Prevention:**

P201 Obtain special instructions before use.  
P261 Avoid breathing dust.  
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

**Response:**

P304 + P340 + P312 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER/ doctor if you feel unwell.  
P305 + P351 + P338 + P310 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Immediately call a POISON CENTER/ doctor.  
P308 + P313 IF exposed or concerned: Get medical advice/ attention.

**Hazardous components which must be listed on the label:**

Raltegravir

### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Contact with dust can cause mechanical irritation or drying of the skin.  
May form explosive dust-air mixture during processing, handling or other means.

## SECTION 3: Composition/information on ingredients

### 3.2 Mixtures

#### Components

| Chemical name | CAS-No.<br>EC-No.<br>Index-No.<br>Registration number | Classification  | Concentration<br>(% w/w) |
|---------------|---|---|--------------------------|
| Raltegravir   | 871038-72-1   | Eye Dam. 1; H318<br>Repr. 2; H361d<br>STOT SE 3; H335 | >= 20 - < 30             |

For explanation of abbreviations see section 16.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Raltegravir Pediatric Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 20.03.2023  |
| 3.1     | 26.09.2023     | 20369-00025 | Date of first issue: 09.10.2014 |

---

### SECTION 4: First aid measures

#### 4.1 Description of first aid measures

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- If inhaled : If inhaled, remove to fresh air.  
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.  
Remove contaminated clothing and shoes.  
Get medical attention.  
Wash clothing before reuse.  
Thoroughly clean shoes before reuse.
- In case of eye contact : In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.  
If easy to do, remove contact lens, if worn.  
Get medical attention immediately.
- If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention.  
Rinse mouth thoroughly with water.

#### 4.2 Most important symptoms and effects, both acute and delayed

- Risks : Causes serious eye damage.  
May cause respiratory irritation.  
Suspected of damaging the unborn child.
- Contact with dust can cause mechanical irritation or drying of the skin.

#### 4.3 Indication of any immediate medical attention and special treatment needed

- Treatment : Treat symptomatically and supportively.
- 

### SECTION 5: Firefighting measures

#### 5.1 Extinguishing media

- Suitable extinguishing media : Water spray  
Alcohol-resistant foam
-

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Raltegravir Pediatric Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 20.03.2023  |
| 3.1     | 26.09.2023     | 20369-00025 | Date of first issue: 09.10.2014 |

---

Carbon dioxide (CO<sub>2</sub>)  
Dry chemical

Unsuitable extinguishing media : None known.

### 5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.  
Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides  
Nitrogen oxides (NO<sub>x</sub>)  
Fluorine compounds  
Chlorine compounds  
Sulphur oxides  
Metal oxides

### 5.3 Advice for firefighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

---

## SECTION 6: Accidental release measures

### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

### 6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

### 6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Surround spill with absorbents and place a damp covering over the area to minimise entry of the material into the air.  
Add excess liquid to allow the material to enter into solution.  
Soak up with inert absorbent material.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Raltegravir Pediatric Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 20.03.2023  |
| 3.1     | 26.09.2023     | 20369-00025 | Date of first issue: 09.10.2014 |

Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).  
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.  
Clean up remaining materials from spill with suitable absorbent.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

## SECTION 7: Handling and storage

### 7.1 Precautions for safe handling

- Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.  
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
- Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.
- Advice on safe handling : Avoid breathing dust.  
Do not swallow.  
Do not get in eyes.  
Avoid prolonged or repeated contact with skin.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Keep container tightly closed.  
Already sensitised individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respiratory irritants or sensitisers.  
Minimize dust generation and accumulation.  
Keep container closed when not in use.  
Keep away from heat and sources of ignition.  
Take precautionary measures against static discharges.  
Take care to prevent spills, waste and minimize release to the environment.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

### 7.2 Conditions for safe storage, including any incompatibilities

- Requirements for storage areas and containers : Keep in properly labelled containers. Store locked up. Keep tightly closed. Keep in a cool, well-ventilated place. Store in

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Raltegravir Pediatric Formulation

Version 3.1      Revision Date: 26.09.2023      SDS Number: 20369-00025      Date of last issue: 20.03.2023  
Date of first issue: 09.10.2014

accordance with the particular national regulations.

Advice on common storage : Do not store with the following product types:  
Strong oxidizing agents

### 7.3 Specific end use(s)

Specific use(s) : No data available

## SECTION 8: Exposure controls/personal protection

### 8.1 Control parameters

#### Occupational Exposure Limits

dusts non-specific      4 mg/m<sup>3</sup>  
Value type (Form of exposure): OELV - 8 hrs (TWA) (Respirable dust)  
Basis: IE OEL

10 mg/m<sup>3</sup>  
Value type (Form of exposure): OELV - 8 hrs (TWA) (inhalable dust)  
Basis: IE OEL

| Components  | CAS-No.     | Value type (Form of exposure) | Control parameters             | Basis    |
|-------------|-------------|-------------------------------|--------------------------------|----------|
| Raltegravir | 871038-72-1 | TWA                           | 1000 µg/m <sup>3</sup> (OEB 1) | Internal |

#### Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

| Substance name  | End Use   | Exposure routes | Potential health effects   | Value                   |
|---|-----------|-----------------|----------------------------|-------------------------|
| 1,2-Benzisothiazol-3(2H)-one 1,1-dioxide, sodium salt | Workers   | Inhalation      | Long-term systemic effects | 1.68 mg/m <sup>3</sup>  |
|   | Workers   | Skin contact    | Long-term systemic effects | 0.952 mg/kg bw/day      |
|   | Consumers | Inhalation      | Long-term systemic effects | 0.414 mg/m <sup>3</sup> |
|   | Consumers | Skin contact    | Long-term systemic effects | 0.476 mg/kg bw/day      |
|   | Consumers | Ingestion       | Long-term systemic effects |                         |

#### Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

| Substance name  | Environmental Compartment | Value        |
|---|---------------------------|--------------|
| 1,2-Benzisothiazol-3(2H)-one 1,1-dioxide, sodium salt | Fresh water               | 0.0158 mg/l  |
|   | Marine water              | 0.00158 mg/l |
|   | Intermittent use/release  | 0.158 mg/l   |

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Raltegravir Pediatric Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 20.03.2023  |
| 3.1     | 26.09.2023     | 20369-00025 | Date of first issue: 09.10.2014 |

---

### 8.2 Exposure controls

#### Engineering measures

Minimize workplace exposure concentrations.  
Apply measures to prevent dust explosions.  
Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).  
If sufficient ventilation is unavailable, use with local exhaust ventilation.

#### Personal protective equipment

|                          |   |   |
|--------------------------|---|---|
| Eye/face protection      | : | Wear the following personal protective equipment:<br>Chemical resistant goggles must be worn.<br>If splashes are likely to occur, wear:<br>Face-shield<br>Equipment should conform to I.S. EN 166   |
| Hand protection          | : |   |
| Material                 | : | Chemical-resistant gloves   |
| Remarks                  | : | Choose gloves to protect hands against chemicals depending on the concentration and quantity of the hazardous substance and specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday. |
| Skin and body protection | : | Select appropriate protective clothing based on chemical resistance data and an assessment of the local exposure potential.<br>Skin contact must be avoided by using impervious protective clothing (gloves, aprons, boots, etc).   |
| Respiratory protection   | : | If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.<br>Equipment should conform to I.S. EN 143   |
| Filter type              | : | Particulates type (P)   |

---

## SECTION 9: Physical and chemical properties

### 9.1 Information on basic physical and chemical properties

|                                   |   |                   |
|-----------------------------------|---|-------------------|
| Physical state                    | : | powder            |
| Colour                            | : | yellow-orange     |
| Odour                             | : | No data available |
| Odour Threshold                   | : | No data available |
| Melting point/freezing point      | : | No data available |
| Initial boiling point and boiling | : | No data available |

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Raltegravir Pediatric Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 20.03.2023  |
| 3.1     | 26.09.2023     | 20369-00025 | Date of first issue: 09.10.2014 |

---

range

Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Flash point : No data available

Auto-ignition temperature : No data available

Decomposition temperature : No data available

pH : No data available

Viscosity

Viscosity, kinematic : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-octanol/water : No data available

Vapour pressure : No data available

Relative density : No data available

Relative vapour density : No data available

Particle characteristics

Particle size : No data available

### 9.2 Other information

Explosives : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Evaporation rate : No data available

Molecular weight : No data available



# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Raltegravir Pediatric Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 20.03.2023  |
| 3.1     | 26.09.2023     | 20369-00025 | Date of first issue: 09.10.2014 |

---

### SECTION 10: Stability and reactivity

#### 10.1 Reactivity

Not classified as a reactivity hazard.

#### 10.2 Chemical stability

Stable under normal conditions.

#### 10.3 Possibility of hazardous reactions

Hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.  
Can react with strong oxidizing agents.

#### 10.4 Conditions to avoid

Conditions to avoid : Heat, flames and sparks.  
Avoid dust formation.

#### 10.5 Incompatible materials

Materials to avoid : Oxidizing agents

#### 10.6 Hazardous decomposition products

No hazardous decomposition products are known.

---

### SECTION 11: Toxicological information

#### 11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of exposure : Inhalation  
Skin contact  
Ingestion  
Eye contact

#### Acute toxicity

Not classified based on available information.

#### Components:

##### Raltegravir:

Acute oral toxicity : LD50 (Mouse, male and female): > 2,000 mg/kg

#### Skin corrosion/irritation

Not classified based on available information.

#### Components:

##### Raltegravir:

Species : Rabbit  
Result : No skin irritation

#### Serious eye damage/eye irritation

Causes serious eye damage.

---

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Raltegravir Pediatric Formulation

Version 3.1      Revision Date: 26.09.2023      SDS Number: 20369-00025      Date of last issue: 20.03.2023  
Date of first issue: 09.10.2014

---

### Components:

#### **Raltegravir:**

Species : Bovine cornea  
Result : Severe irritation

#### **Respiratory or skin sensitisation**

##### **Skin sensitisation**

Not classified based on available information.

##### **Respiratory sensitisation**

Not classified based on available information.

### Components:

#### **Raltegravir:**

Test Type : Local lymph node assay (LLNA)  
Species : Mouse  
Result : negative

#### **Germ cell mutagenicity**

Not classified based on available information.

### Components:

#### **Raltegravir:**

Genotoxicity in vitro : Test Type: reverse mutation assay  
Result: negative  
  
Test Type: Alkaline elution assay  
Test system: rat hepatocytes  
Result: negative  
  
Test Type: Chromosomal aberration  
Method: OECD Test Guideline 473  
Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test  
Species: Mouse  
Result: negative  
  
Test Type: Chromosomal aberration  
Method: OECD Test Guideline 475  
Result: negative

#### **Carcinogenicity**

Not classified based on available information.

### Components:

#### **Raltegravir:**

Species : Mouse, male and female

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Raltegravir Pediatric Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 20.03.2023  |
| 3.1     | 26.09.2023     | 20369-00025 | Date of first issue: 09.10.2014 |

Exposure time : 104 weeks  
Result : negative

### Reproductive toxicity

Suspected of damaging the unborn child.

#### Components:

##### Raltegravir:

Effects on fertility : Test Type: Fertility/early embryonic development  
Species: Rat, male and female  
Application Route: Oral  
General Toxicity - Parent: NOAEL: 600 mg/kg body weight  
Result: negative

Effects on foetal development : Species: Rat  
Application Route: Oral  
General Toxicity Maternal: NOAEL:  $\geq$  600 mg/kg body weight  
Teratogenicity: LOAEL F1: 300 mg/kg body weight  
Symptoms: Skeletal malformations  
Result: positive

Species: Rabbit  
General Toxicity Maternal: NOAEL:  $\geq$  1,000 mg/kg body weight  
Teratogenicity: NOAEL:  $\geq$  1,000 mg/kg body weight  
Result: negative

Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments.

### STOT - single exposure

May cause respiratory irritation.

#### Components:

##### Raltegravir:

Exposure routes : Inhalation  
Target Organs : Respiratory Tract  
Assessment : May cause respiratory irritation.

### STOT - repeated exposure

Not classified based on available information.

### Repeated dose toxicity

#### Components:

##### Raltegravir:

Species : Dog  
NOAEL : 90 mg/kg  
Application Route : Oral

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Raltegravir Pediatric Formulation

Version 3.1      Revision Date: 26.09.2023      SDS Number: 20369-00025      Date of last issue: 20.03.2023  
Date of first issue: 09.10.2014

---

Exposure time : 371 d  
Symptoms : Vomiting

Species : Rat  
NOAEL : 30 mg/kg  
LOAEL : 120 mg/kg  
Application Route : Oral  
Exposure time : 189 d  
Target Organs : Stomach

Species : Mouse  
NOAEL : 50 mg/kg  
LOAEL : 500 mg/kg  
Application Route : Oral  
Exposure time : 14 Weeks  
Target Organs : Stomach

Species : Rat  
NOAEL : 50 mg/kg  
LOAEL : 200 mg/kg  
Application Route : Oral  
Exposure time : 8 Weeks  
Target Organs : Stomach

### Aspiration toxicity

Not classified based on available information.

## 11.2 Information on other hazards

### Endocrine disrupting properties

#### Product:

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

### Experience with human exposure

#### Components:

##### Raltegravir:

Ingestion : Symptoms: Nausea, Diarrhoea, Headache, Fever, Rash, Skin irritation

---

## SECTION 12: Ecological information

### 12.1 Toxicity

#### Components:

##### Raltegravir:

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Raltegravir Pediatric Formulation

Version 3.1      Revision Date: 26.09.2023      SDS Number: 20369-00025      Date of last issue: 20.03.2023  
Date of first issue: 09.10.2014

- Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203
- LC50 (Cyprinodon variegatus (sheepshead minnow)): > 100 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203
- Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202
- Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): 66 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 201
- NOEC (Pseudokirchneriella subcapitata (green algae)): 3.8 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 201
- Toxicity to microorganisms : EC50 : > 1,000 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209
- NOEC : 1,000 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209
- Toxicity to fish (Chronic toxicity) : NOEC: 9.3 mg/l  
Exposure time: 33 d  
Species: Pimephales promelas (fathead minnow)  
Method: OECD Test Guideline 210
- Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC: 9.5 mg/l  
Exposure time: 21 d  
Species: Daphnia magna (Water flea)  
Method: OECD Test Guideline 211

### 12.2 Persistence and degradability

#### Components:

##### **Raltegravir:**

- Biodegradability : Result: rapidly degradable  
Biodegradation: 50 %  
Exposure time: 9 d  
Method: OECD Test Guideline 302B
- Stability in water : Hydrolysis: < 10 %(5 d)

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Raltegravir Pediatric Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 20.03.2023  |
| 3.1     | 26.09.2023     | 20369-00025 | Date of first issue: 09.10.2014 |

---

Method: OECD Test Guideline 111

### 12.3 Bioaccumulative potential

#### Components:

##### **Raltegravir:**

Partition coefficient: n-octanol/water : log Pow: -0.328

### 12.4 Mobility in soil

No data available

### 12.5 Results of PBT and vPvB assessment

#### Product:

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

### 12.6 Endocrine disrupting properties

#### Product:

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

### 12.7 Other adverse effects

No data available

---

## SECTION 13: Disposal considerations

### 13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

---

## SECTION 14: Transport information

### 14.1 UN number or ID number

ADN : Not regulated as a dangerous good

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Raltegravir Pediatric Formulation

Version 3.1      Revision Date: 26.09.2023      SDS Number: 20369-00025      Date of last issue: 20.03.2023  
Date of first issue: 09.10.2014

---

**ADR** : Not regulated as a dangerous good  
**RID** : Not regulated as a dangerous good  
**IMDG** : Not regulated as a dangerous good  
**IATA** : Not regulated as a dangerous good

### 14.2 UN proper shipping name

**ADN** : Not regulated as a dangerous good  
**ADR** : Not regulated as a dangerous good  
**RID** : Not regulated as a dangerous good  
**IMDG** : Not regulated as a dangerous good  
**IATA** : Not regulated as a dangerous good

### 14.3 Transport hazard class(es)

**ADN** : Not regulated as a dangerous good  
**ADR** : Not regulated as a dangerous good  
**RID** : Not regulated as a dangerous good  
**IMDG** : Not regulated as a dangerous good  
**IATA** : Not regulated as a dangerous good

### 14.4 Packing group

**ADN** : Not regulated as a dangerous good  
**ADR** : Not regulated as a dangerous good  
**RID** : Not regulated as a dangerous good  
**IMDG** : Not regulated as a dangerous good  
**IATA (Cargo)** : Not regulated as a dangerous good  
**IATA (Passenger)** : Not regulated as a dangerous good

### 14.5 Environmental hazards

Not regulated as a dangerous good

### 14.6 Special precautions for user

Not applicable

### 14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

---

## SECTION 15: Regulatory information

### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, : Not applicable

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Raltegravir Pediatric Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 20.03.2023  |
| 3.1     | 26.09.2023     | 20369-00025 | Date of first issue: 09.10.2014 |

mixtures and articles (Annex XVII)  
REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59) : Not applicable  
Regulation (EC) No 1005/2009 on substances that deplete the ozone layer : Not applicable  
Regulation (EU) 2019/1021 on persistent organic pollutants (recast) : Not applicable  
Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals : Not applicable  
REACH - List of substances subject to authorisation (Annex XIV) : Not applicable  
Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.  
Not applicable

### Other regulations:

Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable.

### The components of this product are reported in the following inventories:

AICS : not determined  
DSL : not determined  
IECSC : not determined

## 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

## SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

### Full text of H-Statements

H318 : Causes serious eye damage.  
H335 : May cause respiratory irritation.  
H361d : Suspected of damaging the unborn child.

### Full text of other abbreviations

Eye Dam. : Serious eye damage  
Repr. : Reproductive toxicity  
STOT SE : Specific target organ toxicity - single exposure  
IE OEL : List of Chemical Agents and Carcinogens with Occupational Exposure Limit Values - Code of Practice, Schedule 1 and 2  
IE OEL / OELV - 8 hrs (TWA) : Occupational exposure limit value (8-hour reference period)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by



# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Raltegravir Pediatric Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 20.03.2023  |
| 3.1     | 26.09.2023     | 20369-00025 | Date of first issue: 09.10.2014 |

Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

### Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

### Classification of the mixture:

|            |       |
|------------|-------|
| Eye Dam. 1 | H318  |
| Repr. 2    | H361d |
| STOT SE 3  | H335  |

### Classification procedure:

|                    |
|--------------------|
| Calculation method |
| Calculation method |
| Calculation method |

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Raltegravir Pediatric Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 20.03.2023  |
| 3.1     | 26.09.2023     | 20369-00025 | Date of first issue: 09.10.2014 |

---